Literature DB >> 16000294

Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.

Klaas P Koopmans1, Adrienne H Brouwers, Marjolijn N De Hooge, Anouk N Van der Horst-Schrivers, Ido P Kema, Bruce H Wolffenbuttel, Elisabeth G De Vries, Pieter L Jager.   

Abstract

A carcinoid crisis is a severe complication of the carcinoid syndrome that can arise in patients with advanced metastatic neuroendocrine tumors. It can be initiated by stress, catecholamines, and tumor manipulation. In this article, we report a case in which an injection with the catecholamine tracer 6-18F-fluorodihydroxyphenylalanine, used for PET, induced a carcinoid crisis. Octreotide can be used for treatment and should be available. Tracer injection should be slow.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000294

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  A practical, automated synthesis of meta-[(18)F]fluorobenzylguanidine for clinical use.

Authors:  Bao Hu; Amy L Vāvere; Kiel D Neumann; Barry L Shulkin; Stephen G DiMagno; Scott E Snyder
Journal:  ACS Chem Neurosci       Date:  2015-09-11       Impact factor: 4.418

2.  18F-DOPA PET/CT and neuroendocrine tumours.

Authors:  Cristina Nanni; Domenico Rubello; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05       Impact factor: 9.236

3.  Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.

Authors:  Murat Fani Bozkurt; Irene Virgolini; Sona Balogova; Mohsen Beheshti; Domenico Rubello; Clemens Decristoforo; Valentina Ambrosini; Andreas Kjaer; Roberto Delgado-Bolton; Jolanta Kunikowska; Wim J G Oyen; Arturo Chiti; Francesco Giammarile; Anders Sundin; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-25       Impact factor: 9.236

Review 4.  Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.

Authors:  Jessica E Maxwell; Boris Naraev; Daniel M Halperin; Michael A Choti; Thorvardur R Halfdanarson
Journal:  Ann Surg Oncol       Date:  2022-02-14       Impact factor: 5.344

Review 5.  Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging.

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Adil Al-Nahhas; Thirumalesha D Venkatanarayana; Alberto Mazza; Giuseppe Opocher; Domenico Rubello
Journal:  Nucl Med Commun       Date:  2013-12       Impact factor: 1.690

Review 6.  6-[18F]fluoro-L-DOPA: a well-established neurotracer with expanding application spectrum and strongly improved radiosyntheses.

Authors:  M Pretze; C Wängler; B Wängler
Journal:  Biomed Res Int       Date:  2014-05-28       Impact factor: 3.411

Review 7.  Complications from carcinoid syndrome: review of the current evidence.

Authors:  José Mauricio Mota; Luana Guimarães Sousa; Rachel P Riechelmann
Journal:  Ecancermedicalscience       Date:  2016-08-08

Review 8.  Advances in the automated synthesis of 6-[18F]Fluoro-L-DOPA.

Authors:  Ângela C B Neves; Ivanna Hrynchak; Inês Fonseca; Vítor H P Alves; Mariette M Pereira; Amílcar Falcão; Antero J Abrunhosa
Journal:  EJNMMI Radiopharm Chem       Date:  2021-03-10

9.  GMP production of 6-[18F]Fluoro-L-DOPA for PET/CT imaging by different synthetic routes: a three center experience.

Authors:  Valdemar L Andersen; Mikkel A Soerensen; Johan Hygum Dam; Niels Langkjaer; Henrik Petersen; Dirk Andreas Bender; Dan Fugloe; Tri Hien Viet Huynh
Journal:  EJNMMI Radiopharm Chem       Date:  2021-06-12

Review 10.  Nucleophilic Synthesis of 6-l-[18F]FDOPA. Is Copper-Mediated Radiofluorination the Answer?

Authors:  Raisa N Krasikova
Journal:  Molecules       Date:  2020-09-23       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.